The prevalence of chronic kidney disease (CKD) is increasing in Canada with prevalence rates reaching up to 12.5% (3 million Canadian adults), and 3.1% (0.73 million adults) for stages 3-5. Advanced CKD requiring dialysis is expensive and is associated with poor health outcomes and quality of life. To report symptom burden and quality of life adjusted-survival alongside clinical and laboratory measures, it is imperative to measure and report what is important to patients.
Patient-reported outcome measures (PROMs) could be used to capture patients’ experiences of symptoms and impact of disease on functioning, and can support clinicians to monitor disease progression and facilitate patient-centered care. While evidence suggests that the use of PROMs in clinical practice have a positive impact, the impact on health outcomes and experiences is not fully understood, and their cost-effectiveness in clinical settings is unknown. This research aims fill these gaps by evaluating the impact of routinely measuring and reporting to care providers of PROMs on patient-reported experience and outcomes, clinical outcomes, and healthcare utilization.